GlassScriptPhysician profile
Adrian D Velasquez
NPI 1780870659
$6,232.60
in general payments reported to CMS, 2019-2025
23 companies · $987 in 2025
The $987 reported for 2025 was more than what a typical Sleep Medicine (Internal Medicine) provider received nationally (typical 2025 total: $447).
See the full distribution for Sleep Medicine (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $432 · 2022: $1,723 · 2023: $1,848 · 2024: $1,243 · 2025: $987.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,007 · Travel and Lodging: $70.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,007.01 |
| Travel and Lodging | $70.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $2,789.17 | 2022-2025 | Inspire |
| Zoll Respicardia, INC. | $1,198.60 | 2023-2025 | Remede System |
| Novo Nordisk INC | $556.10 | 2021-2023 | Wegovy |
| Harmony Biosciences LLC | $318.49 | 2022-2025 | |
| 3b Medical, INC. | $278.36 | 2023-2024 | Luna |
| Axsome Therapeutics, INC. | $188.00 | 2023-2025 | Sunosi |
| Fisher & Paykel Healthcare INC | $143.81 | 2025 | Fisher & Paykel Healthcare |
| Eisai INC. | $118.27 | 2023 | |
| Abbott Laboratories | $98.11 | 2024 | Freestyle Libre 3 |
| Aimmune Therapeutics, INC. | $81.21 | 2024-2025 | Zenpep, Vowst |
| Phathom Pharmaceuticals, INC. | $79.06 | 2024 | Voquezna |
| Resmed Corp | $60.27 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $46.29 | 2021-2022 | |
| Lilly USA, LLC | $44.74 | 2023-2025 | Zepbound, Mounjaro |
| Amgen INC. | $42.67 | 2022-2023 | Repatha |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $42.24 | 2021-2024 | Airsupra |
| Novartis Pharmaceuticals Corporation | $39.45 | 2021-2022 | |
| Rgh Enterprises LLC | $23.06 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.27 | 2021 | |
| Bridgebio Pharma, INC. | $18.28 | 2025 | Attruby |
| Pfizer INC. | $16.93 | 2021 | |
| Bausch Health US, LLC | $16.89 | 2023 | Aplenzin |
| Merck Sharp & Dohme LLC | $13.33 | 2023 | Steglujan, Steglatro, Belsomra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adrian Velasquez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.